BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Biosimilars
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Radiopharmaceuticals
    • Science '22 in Review
    • Top Biopharma Trends of 2022
    • Top Med-tech Trends of 2022
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • sign in
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, September 25, 2023
Home » Blogs » BioWorld Perspectives » ‘Indirect’ Fat Clogging NIH’s Arteries

BioWorld Perspectives
BioWorld Perspectives RSS FeedRSS

BioWorld / NIH

‘Indirect’ Fat Clogging NIH’s Arteries

March 12, 2013
By Mari Serebrov
No Comments

In the days before the sequester tightened Washington’s belt, the National Institutes of Health (NIH) and several other federal agencies sent up warning shots of just what was at stake. Under the automatic budget cuts intended to put the national deficit on a strict diet, the NIH expected to lose $1.6 billion from its 2013 fiscal budget.

If the sequester stayed in place, NIH Director Francis Collins said the agency would give "hundreds and hundreds" fewer grants than it would have awarded otherwise, slowing down important research. Speaking at a news conference, Collins said the NIH was trying to avoid employee furloughs, but he couldn't promise they wouldn’t occur.

That’s when someone asked a question that others were likely thinking: “Doesn’t the NIH have any fat it can trim?”

“No,” was the reply, especially since the sequester was falling on the heels of several years of nearly flat budgets for the agency. Collins pointed out that because of those flat budgets, the NIH has lost about 20 percent of its spending power in recent years.

Collins painted a similarly bleak picture last year when he testified before a House subcommittee. Even without the sequester, researchers had only a 17 percent chance of getting NIH grant funding, one of the lowest rates in history, he told the Energy and Commerce's Health Subcommittee. In years past, a researcher had a 30 percent chance at funding.

Today, the average age of a researcher getting a first grant is 43. That fact is enough to send young scientists into other careers, depleting the next generation of researchers and jeopardizing the nation’s status as a leader in medical R&D.

While the numbers are discouraging, there is something that would enable the NIH to fund more researchers and stretch its limited research dollars, even under sequestration. The solution? Limit the indirect costs universities can take from agency grants to cover facilities and administration (F&A).

While many foundations spend less than 25 percent of their grants on indirect costs, some universities are spending up to 95 percent on overhead, Rep. Tim Murphy (R-Pa.) said at the subcommittee hearing last year. Repeating a previous conversation with Collins, Murphy listed several private universities that charge excessive indirect costs on NIH grants but spend little of their own money on research. For instance, Harvard University, which has an endowment bigger than the NIH budget, applied 75 percent of its NIH funding to overhead costs and spent zero of its own funding, the congressman said.

Such practices aren’t limited to NIH grants, as the F&A rates for research grants are calculated in accordance with federal-wide guidelines issued by the Office of Management and Budget. “F&A cost rates are negotiated and established by the federal government to ensure that they are fair and equitable and that the federal government pays its fair share of these costs,” NIH told BioWorld recently.

Given current budget constraints and the fact that many universities are making money by licensing the intellectual property resulting from NIH-funded research, it may be time to rethink the government’s “fair share” of those F&A costs. Putting tighter caps on indirect costs would give the NIH more money to fund its core mission of research rather than subsidizing universities that will profit from that research.

Editor's note: How much NIH grant money should go toward indirect costs such as facilities and administration? Cast your vote at bioworld.com. Look for our poll on the bottom, right side.

You must login or register in order to post a comment.

Report Abusive Comment

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Sept. 22, 2023.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for September 22, 2023.
  • Hands holding torn contract

    Quite a fix: Orthofix sacks three top execs

    BioWorld MedTech
    Orthofix Medical Inc. terminated its CEO, chief financial officer and chief legal officer in a move that plunged the stock from $18.63 at Monday’s close to $13.01...
  • Illustration of Alzheimer’s in the brain.

    Study identifies cause of death for Alzheimer’s neurons

    BioWorld
    By creating a new mouse model of Alzheimer’s disease that better recapitulated how the disease plays out in humans, investigators at KU Leuven have gained new...
  • 3D illustration of cancer in crosshairs

    Dato data lack means upside for Gilead; Padcev 'must-win' does win

    BioWorld
    Upbeat phase III findings outweighed less encouraging late-stage trial news, as big pharma provided a mixed bag of cancer findings – with one data batch to form...
BioFuture ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing